HUE050007T2 - Immunglobulin variábilis domének - Google Patents

Immunglobulin variábilis domének

Info

Publication number
HUE050007T2
HUE050007T2 HUE15722211A HUE15722211A HUE050007T2 HU E050007 T2 HUE050007 T2 HU E050007T2 HU E15722211 A HUE15722211 A HU E15722211A HU E15722211 A HUE15722211 A HU E15722211A HU E050007 T2 HUE050007 T2 HU E050007T2
Authority
HU
Hungary
Prior art keywords
variable domains
immunoglobulin variable
immunoglobulin
domains
variable
Prior art date
Application number
HUE15722211A
Other languages
English (en)
Hungarian (hu)
Inventor
Marie-Ange Buyse
Carlo Boutton
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of HUE050007T2 publication Critical patent/HUE050007T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HUE15722211A 2014-05-16 2015-05-13 Immunglobulin variábilis domének HUE050007T2 (hu)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201461994552P 2014-05-16 2014-05-16
US201461014015P 2014-06-18 2014-06-18
US201462014015P 2014-06-18 2014-06-18
US201462040167P 2014-08-21 2014-08-21
US201462047560P 2014-09-08 2014-09-08
US201562133600P 2015-03-16 2015-03-16

Publications (1)

Publication Number Publication Date
HUE050007T2 true HUE050007T2 (hu) 2020-11-30

Family

ID=91193230

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE15722211A HUE050007T2 (hu) 2014-05-16 2015-05-13 Immunglobulin variábilis domének
HUE17178990A HUE058008T2 (hu) 2014-05-16 2015-05-13 Immunglobulin variábilis domének

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE17178990A HUE058008T2 (hu) 2014-05-16 2015-05-13 Immunglobulin variábilis domének

Country Status (24)

Country Link
US (10) US12180268B2 (enExample)
EP (4) EP3143042B1 (enExample)
JP (6) JP7325928B2 (enExample)
KR (5) KR20170002645A (enExample)
CN (3) CN113717280A (enExample)
AU (5) AU2015261536B2 (enExample)
BR (2) BR122018009619B1 (enExample)
CA (2) CA3175002A1 (enExample)
DK (2) DK3143042T3 (enExample)
ES (2) ES2815572T3 (enExample)
HR (2) HRP20220400T1 (enExample)
HU (2) HUE050007T2 (enExample)
IL (6) IL295534B2 (enExample)
LT (2) LT3143042T (enExample)
MX (4) MX383560B (enExample)
PH (1) PH12016502282B1 (enExample)
PL (2) PL3143042T3 (enExample)
PT (2) PT3143042T (enExample)
RS (2) RS60717B1 (enExample)
RU (1) RU2746738C2 (enExample)
SG (3) SG10201810124PA (enExample)
SI (2) SI3143042T1 (enExample)
WO (1) WO2015173325A2 (enExample)
ZA (5) ZA201607587B (enExample)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
KR101965462B1 (ko) 2011-06-23 2019-04-04 아블린쓰 엔.브이. 면역글로불린 단일 가변 도메인을 수반하는 어세이에서 비특이적 단백질 간섭을 예측하고 검출하고 감소시키는 기법
IL318433A (en) 2014-05-16 2025-03-01 Ablynx Nv Improved immunoglobulin variable complexes
AU2015261536B2 (en) 2014-05-16 2020-05-07 Ablynx Nv Improved immunoglobulin variable domains
CN107531777A (zh) 2015-01-21 2018-01-02 英伊布里克斯有限合伙公司 非免疫原性单结构域抗体
NO2768984T3 (enExample) 2015-11-12 2018-06-09
CN108431039B (zh) * 2015-11-12 2022-06-28 埃博灵克斯股份有限公司 改进的p2x7受体结合剂和包含其的多肽
EP3974449A1 (en) 2015-11-13 2022-03-30 Ablynx NV Improved serum albumin-binding immunoglobulin variable domains
CA3003777A1 (en) 2015-11-18 2017-05-26 Merck Sharp & Dohme Corp. Pd1/ctla4 binders
TWI754622B (zh) 2015-11-18 2022-02-11 美商默沙東藥廠 Ctla4結合劑
JP7046804B2 (ja) * 2015-11-18 2022-04-04 アブリンクス エン．ヴェー． 改良された血清アルブミン結合剤
HK1254951A1 (zh) 2015-11-18 2019-08-02 Merck Sharp & Dohme Llc Pd1和/或lag3结合剂
WO2017137579A1 (en) 2016-02-12 2017-08-17 Ablynx Nv Method for the production of immunoglobulin single variable domains
CN107400166A (zh) * 2016-05-19 2017-11-28 苏州康宁杰瑞生物科技有限公司 针对ctla4的单域抗体及其衍生蛋白
WO2017220645A1 (en) 2016-06-23 2017-12-28 Ablynx N.V. Improved pharmacokinetic assays for immunoglobulin single variable domains
KR20240076829A (ko) 2016-11-16 2024-05-30 아블린쓰 엔.브이. Cd123 및 tcr 알파/베타에 결합할 수 있는 t 세포 동원 폴리펩티드
CN110049997B (zh) * 2016-12-07 2023-09-22 埃博灵克斯股份有限公司 改进的血清白蛋白结合免疫球蛋白单可变结构域
EP3571224B1 (en) 2017-01-17 2024-08-07 Ablynx NV Improved serum albumin binders
ES2991459T3 (es) 2017-01-17 2024-12-03 Ablynx Nv Ligantes de albúmina sérica mejorados
LT3630847T (lt) 2017-06-02 2024-12-10 Merck Patent Gmbh Adamts surišantys imunoglobulinai
WO2019016237A1 (en) 2017-07-19 2019-01-24 Vib Vzw AGENTS FOR CONNECTING TO SERUM ALBUMIN
WO2019086548A1 (en) 2017-10-31 2019-05-09 Vib Vzw Novel antigen-binding chimeric proteins and methods and uses thereof
WO2020176478A1 (en) 2019-02-25 2020-09-03 The University Of Chicago Methods and compositions for treating inflammatory and autoimmune conditions with ecm-affinity peptides linked to anti-inflammatory agents
WO2020221888A1 (en) 2019-04-30 2020-11-05 Vib Vzw Cystic fibrosis transmembrane conductance regulator stabilizing agents
WO2021105438A1 (en) 2019-11-27 2021-06-03 Vib Vzw Positive allosteric modulators of the calcium-sensing receptor
JP7657797B2 (ja) * 2019-12-06 2025-04-07 アブリンクス エン．ヴェー． ＴＮＦαおよびＩＬ－２３を標的化する免疫グロブリン単一可変ドメインを含むポリペプチド
JP7719775B2 (ja) 2019-12-06 2025-08-06 アブリンクス エン．ヴェー． ＴＮＦαおよびＯＸ４０Ｌを標的とする免疫グロブリン単一可変ドメインを含むポリペプチド
CN114980974A (zh) 2019-12-09 2022-08-30 艾伯霖克斯公司 含靶向il-13和tslp的免疫球蛋白单可变结构域的多肽
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
US20240027467A1 (en) 2019-12-20 2024-01-25 Vib Vzw Nanobody Exchange Chromatography
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
WO2021170540A1 (en) 2020-02-25 2021-09-02 Vib Vzw Leucine-rich repeat kinase 2 allosteric modulators
CN115397868A (zh) 2020-03-30 2022-11-25 埃博灵克斯股份有限公司 用于产生和纯化多价免疫球蛋白单可变域的方法
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
WO2022032040A1 (en) * 2020-08-05 2022-02-10 Synthekine, Inc. Il2rb/il2rg synthetic cytokines
IL301581A (en) 2020-09-25 2023-05-01 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l
EP4255929A2 (en) 2020-12-02 2023-10-11 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
PH12023500013A1 (en) 2020-12-04 2024-03-11 Tidal Therapeutics Inc Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
US11897951B2 (en) 2020-12-18 2024-02-13 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-α
WO2022129637A1 (en) 2020-12-18 2022-06-23 Ablynx Nv T cell recruiting polypeptides based on tcr alpha/beta reactivity
KR20230123495A (ko) 2020-12-18 2023-08-23 아블린쓰 엔.브이. 글리피칸-3 및 t세포 수용체를 표적으로 하는 면역글로불린단일 가변 도메인을 포함하는 폴리펩티드
GB202020502D0 (en) 2020-12-23 2021-02-03 Vib Vzw Antibody composistion for treatment of corona virus infection
CA3207548A1 (en) 2021-02-05 2022-08-11 Xavier Saelens Sarbecovirus binders
CN117794566A (zh) 2021-02-05 2024-03-29 Vib研究所 沙贝病毒结合剂
WO2022175532A1 (en) 2021-02-19 2022-08-25 Vib Vzw Cation-independent mannose-6-phosphate receptor binders
WO2022206900A1 (zh) * 2021-04-01 2022-10-06 江苏先声药业有限公司 抗人血清白蛋白(hsa)的纳米抗体及其应用
CA3228014A1 (en) 2021-07-30 2023-02-16 Vib Vzm Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation
WO2023093899A1 (zh) * 2021-11-29 2023-06-01 江苏恒瑞医药股份有限公司 经修饰的蛋白或多肽
TW202342508A (zh) 2021-12-17 2023-11-01 比利時商艾伯霖克斯公司 包含靶向ＴＣＲαβ、ＣＤ３３和ＣＤ１２３的免疫球蛋白單可變結構域的多肽
US20250304664A1 (en) 2022-01-12 2025-10-02 Vib Vzw Human NTCP Binders For Therapeutic Use And Liver-Specific Targeted Delivery
US20250235534A1 (en) 2022-04-13 2025-07-24 Vib Vzw An LTBR Agonist In Combination Therapy Against Cancer
EP4273162A1 (en) * 2022-05-06 2023-11-08 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
IL316376A (en) 2022-05-06 2024-12-01 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
JP2025517728A (ja) 2022-05-18 2025-06-10 ブイアイビー ブイゼットダブリュ サルベコウイルスのスパイクｓ２サブユニットバインダー
US20240002331A1 (en) 2022-06-08 2024-01-04 Tidal Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
KR20250023503A (ko) 2022-06-14 2025-02-18 아블린쓰 T 세포 수용체를 표적화하는 면역글로불린 단일 가변 도메인
AU2023313033A1 (en) 2022-07-27 2025-03-13 Ablynx Nv Polypeptides binding to a specific epitope of the neonatal fc receptor
EP4594348A1 (en) 2022-09-27 2025-08-06 Vib Vzw Antivirals against human parainfluenza virus
EP4605077A1 (en) 2022-10-18 2025-08-27 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
AR131441A1 (es) 2022-12-21 2025-03-19 Genzyme Corp Proteínas de unión anti-pd-1 ´ 4-1bb
AR131494A1 (es) 2022-12-23 2025-03-26 Ablynx Nv Vehículos de conjugación a base de proteína
CN120529914A (zh) 2023-01-09 2025-08-22 奥德赛治疗股份有限公司 抗tnfr2抗原结合蛋白及其用途
CN121013866A (zh) 2023-02-10 2025-11-25 阿穆尼克斯制药公司 靶向前列腺特异性膜抗原（psma）的组合物及其制备和使用方法
IL322519A (en) 2023-02-17 2025-10-01 Ablynx Nv Polypeptides that bind to the neonatal fc receptor
WO2024175787A1 (en) 2023-02-24 2024-08-29 Vrije Universiteit Brussel Anti-inflammatory pannexin 1 channel inhibitors
AR132121A1 (es) 2023-03-14 2025-05-28 Odyssey Therapeutics Inc Proteínas de unión a antígeno anti-cd25 y usos de las mismas
WO2024208816A1 (en) 2023-04-03 2024-10-10 Vib Vzw Blood-brain barrier crossing antibodies
TW202509060A (zh) 2023-05-08 2025-03-01 法商賽諾菲公司 免疫球蛋白單可變結構域的醣基化
AR132699A1 (es) 2023-05-17 2025-07-23 Odyssey Therapeutics Inc Anticuerpos de dominio único modificados
WO2024261235A1 (en) 2023-06-22 2024-12-26 Ablynx Nv Chimeric proteins for modulating cytokine receptor activity
AR133108A1 (es) 2023-06-29 2025-08-27 Odyssey Therapeutics Inc Proteínas de unión a antígeno anti-trailr2 y sus usos
AR133188A1 (es) 2023-07-05 2025-09-03 Ablynx Nv ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG
TW202525843A (zh) 2023-09-04 2025-07-01 法商賽諾菲公司 用於治療表現磷脂醯肌醇蛋白聚糖-3之腫瘤的多肽
WO2025061919A1 (en) 2023-09-22 2025-03-27 Ablynx Nv Bi- and multivalent albumin binders
TW202530265A (zh) 2023-10-13 2025-08-01 美商奧迪希治療公司 抗cdh17抗原結合蛋白及其用途
TW202540169A (zh) 2023-11-08 2025-10-16 法商賽諾菲公司 基於ｃｄ２５的溶酶體降解物及其用途
WO2025109176A1 (en) 2023-11-22 2025-05-30 Exevir Bio Bv Optimized sarbecovirus spike s2 subunit binders and compositions comprising the same
TW202540188A (zh) 2023-12-01 2025-10-16 比利時商艾伯霖克斯公司 精準活化的多肽
WO2025125577A1 (en) 2023-12-14 2025-06-19 Vib Vzw Antibodies against influenza b virus
WO2025133253A2 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based conjugation carriers for intranuclear delivery
WO2025133166A1 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based carriers for site-specific amine conjugation
WO2025174825A2 (en) 2024-02-12 2025-08-21 Aera Therapeutics, Inc. Delivery compositions
WO2025181155A1 (en) 2024-02-26 2025-09-04 Vib Vzw Human beta-glucocerebrosidase binders and uses thereof
WO2025217240A1 (en) 2024-04-10 2025-10-16 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
US12459994B2 (en) 2024-04-12 2025-11-04 Paragon Therapeutics, Inc. Albumin binding proteins and methods of use
WO2025219231A1 (en) 2024-04-15 2025-10-23 Vib Vzw Computer-implemented means and methods for the de novo design of antibodies targeting a specific epitope
WO2025255558A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof
WO2025255435A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Antigen-binding proteins against serum albumin and uses thereof
WO2025262150A2 (en) 2024-06-18 2025-12-26 Ablynx Nv Antibody-recruiting molecules
WO2026006809A1 (en) 2024-06-27 2026-01-02 Odyssey Therapeutics, Inc. Multispecific molecules binding tnfr2 and cd25 and uses thereof
WO2026006708A2 (en) 2024-06-27 2026-01-02 Odyssey Therapeutics, Inc. Anti-cd25 antigen-binding proteins and uses thereof

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1545106C3 (de) * 1963-07-16 1979-05-31 Union Carbide Corp., New York, N.Y. (V.St.A.) Verfahren zur Herstellung von linearen Polyarylenpolyäthern
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5248775A (en) 1989-12-11 1993-09-28 The Trustees Of Princeton University Pyrrolo(2,3-d)pyrimidines
KR0162654B1 (ko) 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
US4996206A (en) 1989-12-11 1991-02-26 The Trustees Of Princeton University N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
ES2338321T3 (es) 1992-08-21 2010-05-06 Vrije Universiteit Brussel Inmunoglobulinas desprovistas de cadenas ligeras.
BR9907950A (pt) 1998-02-19 2001-12-18 Xcyte Therapies Inc Composições e processos para regulagem deativação de linfócitos
NZ539776A (en) 1999-01-15 2006-12-22 Genentech Inc Polypeptide variants with altered effector function
US7943129B2 (en) * 2000-05-26 2011-05-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
WO2003035695A2 (en) 2001-07-26 2003-05-01 Tanox, Inc. Agents that activate or inhibit toll-like receptor 9
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
EP1600459A3 (en) 2002-06-28 2005-12-07 Domantis Limited Ligand
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
FR2846667B1 (fr) 2002-11-06 2004-12-31 Pasteur Institut Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives
JP2006519763A (ja) 2002-11-08 2006-08-31 アブリンクス エン．ヴェー． 治療用ポリペプチドの投与法およびそのためのポリペプチド
EP1558650A2 (en) 2002-11-08 2005-08-03 Ablynx N.V. Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
CN101412759A (zh) 2003-01-10 2009-04-22 埃博灵克斯股份有限公司 治疗性多肽,其同源物、其片段及其在调节血小板介导的聚集方面的应用
WO2005092925A2 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
US8921528B2 (en) 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
BRPI0518761A2 (pt) 2004-12-02 2008-12-09 Domantis Ltd fusço de droga, conjugado de droga, Ácido nucleico recombinante, construÇço de Ácido nucleico, cÉlula hospedeira, mÉtodo para produzir uma fusço de droga, composiÇço farmacÊutica, droga, mÉtodo de tratamento e/ou prevenÇço de uma condiÇço em um paciente, mÉtodo de retardo ou prevenÇço de progressço de doenÇa, e, mÉtodo para diminuir a absorÇço de alimentos por um paciente
EP1863847A2 (en) 2004-12-02 2007-12-12 Domantis Limited Anti-il-1r1 single domain antibodies and therapeutic uses
MX363423B (es) * 2005-05-18 2019-03-22 Ablynx Nv Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor.
EP3243839A1 (en) 2005-05-20 2017-11-15 Ablynx N.V. Improved nanobodies tm for the treatment of aggregation-mediated disorders
WO2006129843A2 (en) 2005-05-31 2006-12-07 Canon Kabushiki Kaisha Bispecific capturing molecule
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
CN101466734A (zh) 2005-12-01 2009-06-24 杜门蒂斯有限公司 与白细胞介素-1受体1型结合的竞争性域抗体形式
KR20080077238A (ko) 2005-12-01 2008-08-21 도만티스 리미티드 인터루킨 1 수용체 타입 1에 결합하는 비경쟁적 도메인항체 포맷
FR2894741B1 (fr) 2005-12-08 2009-12-04 Centre Nat Etd Spatiales Chaine de reception par satellite
US20100047171A1 (en) 2006-01-24 2010-02-25 Roland Beckmann Fusion Proteins That Contain Natural Junctions
EP2057191A1 (en) 2006-08-18 2009-05-13 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
CA2671581A1 (en) 2006-12-05 2008-06-12 Ablynx N.V. Peptides capable of binding to serum proteins
AU2007331672A1 (en) 2006-12-15 2008-06-19 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system
WO2009138519A1 (en) 2008-05-16 2009-11-19 Ablynx Nv AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
ES2663512T3 (es) 2007-05-24 2018-04-13 Ablynx N.V. Secuencias de aminoácidos dirigidas contra RANK-L y polipéptidos que comprenden las mismas para el tratamiento de enfermedades y trastornos óseos
MX2009013328A (es) 2007-06-25 2010-06-02 Esbatech An Alcon Biomedical R Metodos para modificar anticuerpos, y anticuerpos modificados con propiedades funcionales mejoradas.
WO2009068627A2 (en) 2007-11-27 2009-06-04 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
EA018471B1 (ru) 2008-03-31 2013-08-30 Глаксо Груп Лимитед Слитые конструкции и конъюгаты лекарственного средства
CN102089325A (zh) 2008-04-17 2011-06-08 埃博灵克斯股份有限公司 能够结合血清白蛋白的肽，以及包含其的化合物、构建体和多肽
WO2009138494A2 (en) * 2008-05-15 2009-11-19 Ablynx N.V. Amino acid sequences directed against toll-like receptors and polypeptides comprising the same for the treatment of diseases related to toll-like receptors
DE102008023620A1 (de) 2008-05-15 2009-11-19 Mettler-Toledo (Albstadt) Gmbh Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf
EP2143735A1 (en) * 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US20110200525A1 (en) 2008-10-09 2011-08-18 Patz Jr Edward F Vhh antibody fragments for use in the detection and treatment of cancer
JP2012521971A (ja) 2009-03-27 2012-09-20 グラクソ グループ リミテッド 薬物融合体および複合体
US9464138B2 (en) 2009-04-30 2016-10-11 Ablynx N.V. Method for the production of domain antibodies
WO2010130832A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
US20120264917A1 (en) 2009-05-27 2012-10-18 Ablynx N.V. Biparatopic protein constructs directed against il-23
UY32665A (es) 2009-05-28 2010-12-31 Glaxo Group Ltd Proteinas de union al antigeno
ES2804450T3 (es) 2009-07-10 2021-02-08 Ablynx Nv Método para la producción de dominios variables
US8306355B2 (en) 2009-07-13 2012-11-06 Sharp Laboratories Of America, Inc. Methods and systems for reducing compression artifacts
EP2486056A1 (en) 2009-10-09 2012-08-15 Ablynx N.V. Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them
EP3309176B1 (en) 2009-12-14 2025-10-01 Ablynx N.V. Immunoglobulin single variable domain antibodies against ox40l, constructs and their therapeutic use
MX2012005345A (es) 2009-12-23 2012-06-08 Esbatech Alcon Biomed Res Unit Metodo para disminuir inmunogenicidad.
JP5826194B2 (ja) 2010-03-03 2015-12-02 アブリンクス ナームローゼ フェンノートシャップ 二パラトープ性ａ−ベータ結合ポリペプチド
WO2011117423A1 (en) 2010-03-26 2011-09-29 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
JP2013525408A (ja) 2010-04-30 2013-06-20 アブリンクス エン．ヴェー． ヘテロ二量体サイトカインｉｌ−２３のｐ１９サブユニットに指向性を有するナノボディのアミノ酸配列
SG185354A1 (en) 2010-05-20 2012-12-28 Ablynx Nv Biological materials related to her3
WO2011161266A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Improved immunoglobulin single variable domains and constructs thereof directed against cxcr4
JP2013145769A (ja) 2010-08-04 2013-07-25 Kri Inc 異方性希土類ボンド磁石とその製造方法
WO2012042026A1 (en) 2010-09-30 2012-04-05 Ablynx Nv Biological materials related to c-met
JP2014505698A (ja) 2011-02-02 2014-03-06 グラクソ グループ リミテッド 新規抗原結合タンパク質
JP6181040B2 (ja) 2011-03-28 2017-08-16 アブリンクス エン．ヴェー． 二特異性抗ｃｘｃｒ７免疫グロブリン単一可変ドメイン
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
PT2723771T (pt) 2011-06-23 2019-12-11 Ablynx Nv Proteínas de ligação à albumina sérica
KR101965462B1 (ko) * 2011-06-23 2019-04-04 아블린쓰 엔.브이. 면역글로불린 단일 가변 도메인을 수반하는 어세이에서 비특이적 단백질 간섭을 예측하고 검출하고 감소시키는 기법
AU2012273928A1 (en) 2011-06-23 2014-02-06 Ablynx Nv Immunoglobulin single variable domains directed against IgE
US20130019175A1 (en) 2011-07-14 2013-01-17 Microsoft Corporation Submenus for context based menu system
ES2813432T3 (es) 2011-08-17 2021-03-23 Glaxo Group Ltd Proteínas y péptidos modificados
CN103889451B (zh) 2011-09-30 2016-06-29 埃博灵克斯股份有限公司 与C-Met相关的生物物质
LT3216871T (lt) * 2011-10-17 2022-03-25 Regeneron Pharmaceuticals, Inc. Pelės, turinčios apribotą imunoglobulino sunkiąją grandinę
US20130129727A1 (en) 2011-11-17 2013-05-23 Nanjingjinsirui Science & Technology Biology Corporation Methods and systems for increasing protein stability
CA2862332C (en) * 2012-01-31 2021-05-18 Regeneron Pharmaceuticals, Inc. Anti-asic1 antibodies and uses thereof
CN104507964B (zh) 2012-06-01 2020-05-15 埃博灵克斯股份有限公司 P2x7受体拮抗剂和激动剂
TW201843172A (zh) * 2012-06-25 2018-12-16 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
JP2015531350A (ja) 2012-09-13 2015-11-02 ノバルティス アーゲー 末端修飾を有する抗原結合分子
US9667316B2 (en) 2013-05-17 2017-05-30 The Boeing Company Aircraft data transmission using phase separation
AU2015261536B2 (en) 2014-05-16 2020-05-07 Ablynx Nv Improved immunoglobulin variable domains
CA3003539A1 (en) 2015-10-30 2017-05-04 Ablynx Nv Polypeptides against il-23
NO2768984T3 (enExample) 2015-11-12 2018-06-09
CN108431039B (zh) 2015-11-12 2022-06-28 埃博灵克斯股份有限公司 改进的p2x7受体结合剂和包含其的多肽
EP3974449A1 (en) 2015-11-13 2022-03-30 Ablynx NV Improved serum albumin-binding immunoglobulin variable domains
JP7046804B2 (ja) 2015-11-18 2022-04-04 アブリンクス エン．ヴェー． 改良された血清アルブミン結合剤
HK1254951A1 (zh) 2015-11-18 2019-08-02 Merck Sharp & Dohme Llc Pd1和/或lag3结合剂
CA3003777A1 (en) 2015-11-18 2017-05-26 Merck Sharp & Dohme Corp. Pd1/ctla4 binders
TWI754622B (zh) 2015-11-18 2022-02-11 美商默沙東藥廠 Ctla4結合劑
EP3571224B1 (en) 2017-01-17 2024-08-07 Ablynx NV Improved serum albumin binders
JP7657797B2 (ja) 2019-12-06 2025-04-07 アブリンクス エン．ヴェー． ＴＮＦαおよびＩＬ－２３を標的化する免疫グロブリン単一可変ドメインを含むポリペプチド
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
US11897951B2 (en) 2020-12-18 2024-02-13 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-α

Also Published As

Publication number Publication date
CN109053885A (zh) 2018-12-21
IL281755B1 (en) 2023-01-01
US12180268B2 (en) 2024-12-31
IL311293B1 (en) 2025-03-01
US20210261653A1 (en) 2021-08-26
US20220119512A1 (en) 2022-04-21
JP2024069377A (ja) 2024-05-21
IL295534A (en) 2022-10-01
KR20170002645A (ko) 2017-01-06
JP7471987B2 (ja) 2024-04-22
US11485778B2 (en) 2022-11-01
IL311293B2 (en) 2025-07-01
MX2021007020A (es) 2021-08-05
JP7325928B2 (ja) 2023-08-15
JP2021130681A (ja) 2021-09-09
MX2018007581A (es) 2020-11-12
WO2015173325A2 (en) 2015-11-19
CN113717280A (zh) 2021-11-30
IL311293A (en) 2024-05-01
CN106661100A (zh) 2017-05-10
IL295534B2 (en) 2025-03-01
SI3248986T1 (sl) 2022-04-29
ZA202004757B (en) 2022-08-31
EP3248986A2 (en) 2017-11-29
ZA202100742B (en) 2022-09-28
NZ726448A (en) 2023-02-24
IL295534B1 (en) 2024-11-01
MX2016014926A (es) 2017-05-09
RS63085B1 (sr) 2022-04-29
PH12016502282B1 (en) 2024-05-22
AU2020202855B2 (en) 2022-12-08
RU2746738C2 (ru) 2021-04-20
RU2016149463A (ru) 2018-06-19
LT3143042T (lt) 2020-07-27
KR20180091115A (ko) 2018-08-14
US20220251183A1 (en) 2022-08-11
IL281755A (en) 2021-05-31
KR102827683B1 (ko) 2025-06-30
WO2015173325A3 (en) 2016-02-18
BR122018009619B1 (pt) 2024-01-02
ES2912069T3 (es) 2022-05-24
RS60717B1 (sr) 2020-09-30
EP3143042B1 (en) 2020-06-10
HRP20200966T1 (hr) 2020-10-16
JP7098439B2 (ja) 2022-07-11
IL259972B (en) 2021-04-29
JP2021006563A (ja) 2021-01-21
PL3143042T3 (pl) 2020-11-16
EP3693386A1 (en) 2020-08-12
KR102769509B1 (ko) 2025-02-17
PT3143042T (pt) 2020-09-01
US20220332807A1 (en) 2022-10-20
SG11201609162SA (en) 2016-12-29
SI3143042T1 (sl) 2020-08-31
AU2020202570A1 (en) 2020-05-07
MX383560B (es) 2025-03-14
ZA202004758B (en) 2022-08-31
PL3248986T3 (pl) 2022-05-16
DK3143042T3 (da) 2020-08-31
EP3143042A2 (en) 2017-03-22
IL248636B (en) 2022-12-01
IL259972A (en) 2018-07-31
JP2017518072A (ja) 2017-07-06
AU2015261536B2 (en) 2020-05-07
AU2022279373A1 (en) 2023-01-19
IL248636B2 (en) 2023-04-01
US11312764B2 (en) 2022-04-26
AU2018204226A1 (en) 2018-07-05
IL281755B2 (en) 2023-05-01
AU2020202855A1 (en) 2020-05-21
US20210269515A1 (en) 2021-09-02
AU2022279374A1 (en) 2023-01-19
AU2015261536A1 (en) 2016-11-17
US11319364B2 (en) 2022-05-03
ZA201607587B (en) 2022-05-25
EP3248986A3 (en) 2017-12-20
EP3248986B1 (en) 2022-01-26
IL299282B2 (en) 2024-09-01
IL299282B1 (en) 2024-05-01
US20220332806A1 (en) 2022-10-20
EP3702369A1 (en) 2020-09-02
KR20230145503A (ko) 2023-10-17
RU2018120744A3 (enExample) 2022-01-28
SG10201810124PA (en) 2018-12-28
US20210087261A1 (en) 2021-03-25
KR20230054503A (ko) 2023-04-24
HUE058008T2 (hu) 2022-06-28
ZA202004759B (en) 2022-08-31
RU2016149463A3 (enExample) 2018-07-04
MX2023010731A (es) 2023-09-20
LT3248986T (lt) 2022-03-25
PH12016502282A1 (en) 2017-02-13
PT3248986T (pt) 2022-04-05
JP2018162297A (ja) 2018-10-18
RU2021107470A (ru) 2021-05-17
US20200231662A1 (en) 2020-07-23
BR112016026773A2 (pt) 2017-12-12
CA3175002A1 (en) 2015-11-19
IL248636A0 (en) 2017-01-31
US20220135657A9 (en) 2022-05-05
DK3248986T3 (da) 2022-04-04
CA2948076A1 (en) 2015-11-19
HRP20220400T1 (hr) 2022-05-27
KR20230053002A (ko) 2023-04-20
AU2020202570B2 (en) 2022-12-08
US11220539B2 (en) 2022-01-11
US11485777B2 (en) 2022-11-01
JP7454525B2 (ja) 2024-03-22
JP2024041939A (ja) 2024-03-27
US20170121399A1 (en) 2017-05-04
US11312765B2 (en) 2022-04-26
ES2815572T3 (es) 2021-03-30
US11708404B2 (en) 2023-07-25
IL299282A (en) 2023-02-01
WO2015173325A8 (en) 2016-12-29
US20210269514A1 (en) 2021-09-02
RU2018120744A (ru) 2018-11-15
SG10201805288QA (en) 2018-07-30

Similar Documents

Publication Publication Date Title
IL281755A (en) Enhanced variable complexes of immunoglobulins
IL250583A0 (en) Anti-tigit antibodies
IL252004A0 (en) Ether-substituted antibody
SG11201703403TA (en) Anti-tim-3 antibodies
SG11201703346PA (en) Anti-tim-3 antibodies
IL252422A0 (en) Effector-deficient anti-cd32a antibodies
PT3101131T (pt) Anticorpo antitranstirretina humanizado
IL247322A0 (en) Antibodies to complement factor bb
GB201410520D0 (en) Antibody
IL250374A0 (en) Antibodies against ceramide
IL248220A0 (en) Anti- nme antibody
GB201419092D0 (en) Anti-TIM-3 antibodies
GB201419089D0 (en) Anti-TIM-3 antibodies
GB201417614D0 (en) Antibodies
GB201414270D0 (en) Antibodies
GB201405775D0 (en) Antibodies
GB201401200D0 (en) Antibodies
GB201418776D0 (en) Antibody
GB201413745D0 (en) Antibody
GB201411319D0 (en) Antibody
GB201407535D0 (en) Antibody Drug - Conjugates